Written and maintained by CASRAI Editorial Board
Published
On this page
21 CFR 1308.11 is the section of the Drug Enforcement Administration’s scheduling regulations that lists every substance placed in Schedule I of the Controlled Substances Act. Schedule I is the most restrictive of the five federal schedules: 21 U.S.C. 812(b)(1) requires a finding of a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. The section is a numbered list, not a narrative: each substance carries a DEA Controlled Substances Code Number, and the list is split into paragraphs (b) to (h) by chemical or pharmacological type.
This guide reads the section paragraph by paragraph, shows how to look up an entry, answers the common questions people ask about schedules, and explains what Schedule I status means for a laboratory that wants to work with a listed substance. The regulation text quoted here is the Cornell Legal Information Institute copy of 21 CFR 1308.11 as checked 2026-11-19; the list is amended often, so always check the current text before relying on any single entry.
What 21 CFR 1308.11 is and who runs it
Part 1308 of Title 21 of the Code of Federal Regulations is titled “Schedules of Controlled Substances”. Section 1308.11 is its Schedule I section, and sections 1308.12, 1308.13, 1308.14 and 1308.15 are the Schedule II, III, IV and V sections. The Controlled Substances Act itself, at 21 U.S.C. 812(a), establishes five schedules (I, II, III, IV and V), and the CFR section is where the Drug Enforcement Administration publishes the substances that sit in each.
Paragraph (a) of 1308.11 sets the ground rule: Schedule I consists of the drugs and other substances, “by whatever official name, common or usual name, chemical name, or brand name designated”, listed in the section, and each has been assigned the DEA Controlled Substances Code Number set opposite it. In practice that means the code number is the reliable identifier, because a substance can be known by several names.
A paragraph-by-paragraph map of the section
Most search results for this citation are the raw regulation text. The table below instead shows how the section is organised, using the version checked 2026-11-19.
| Paragraph | Heading in the regulation | What to know before you search it |
|---|---|---|
| (a) | Introduction | Defines Schedule I as the substances listed in the section, by any official, common, chemical or brand name, each with a DEA code number. |
| (b) | Opiates | Numbered (1) to (121) in the text read. The lead-in extends each entry to its isomers, esters, ethers, salts, and salts of isomers, esters and ethers whenever those are possible within the specific chemical designation. |
| (c) | Opium derivatives | Numbered (1) to (23). Includes heroin at (c)(11), code 9200. |
| (d) | Hallucinogenic substances | Numbered (1) to (117). Includes lysergic acid diethylamide at (d)(22), code 7315; marihuana at (d)(23), code 7360; mescaline at (d)(24), code 7381; peyote at (d)(26), code 7415; and tetrahydrocannabinols at (d)(31), code 7370. For this paragraph only, “isomer” includes optical, position and geometric isomers. |
| (e) | Depressants | Numbered (1) to (8). Includes methaqualone at (e)(8), code 2565. |
| (f) | Stimulants | Numbered (1) to (14). Includes cathinone at (f)(4), code 1235. |
| (g) | Cannabimimetic agents | Defined by structural classes rather than a name-by-name list; the heading entry carries code 7000. |
| (h) | Temporary listing of substances subject to emergency scheduling | Paragraphs (1) to (29) are reserved; entries start at (h)(30), fentanyl-related substances, code 9850, and run through (h)(95) in the text read. |
How to read an entry
Each entry has three parts: a position (for example (d)(23)), a name that may include chemical names and other names, and the DEA Controlled Substances Code Number on the line beneath. To check whether a compound is in Schedule I, search the section for its chemical name and its code number, then read the lead-in to the paragraph where it appears. The lead-in matters. Paragraph (b) applies “unless specifically excepted or unless listed in another schedule”, and extends to isomers, esters, ethers and salts “whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation”. Paragraphs (d) to (f) apply the same idea to any material, compound, mixture or preparation containing any quantity of the listed substance.
One entry shows why the detail matters. Under (d)(31), tetrahydrocannabinols are defined as those naturally contained in a cannabis plant and their synthetic equivalents, and (d)(31)(ii) states that the term does not include any material, compound, mixture or preparation that falls within the definition of hemp in 7 U.S.C. 1639o. Marihuana extract is listed separately at (d)(58), code 7350. Anyone whose work touches cannabis-derived material should read the current text of those entries directly rather than rely on a summary.
Temporary listings in paragraph (h)
Paragraph (h) holds substances placed in Schedule I through emergency (temporary) scheduling, and the section’s effective-date notes record that some of these listings run for a fixed period. In the version checked 2026-11-19, the notes state that paragraphs (h)(79) through (85) were added by 90 FR 48265 (October 15, 2025) effective until October 15, 2027, and that paragraph (h)(86) was added by 91 FR 12508 (March 16, 2026) effective until March 16, 2028. Entries (h)(92) to (h)(95) are the most recent in the text read. Because temporary entries come and go, a lab that cites 1308.11 in a protocol should cite the version date it checked.
What does it mean to be a Schedule II drug?
A Schedule II drug is one for which 21 U.S.C. 812(b)(2) requires a finding of a high potential for abuse, a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions, and abuse that may lead to severe psychological or physical dependence. The difference from Schedule I is the medical-use finding: Schedule I requires none, Schedule II requires some, and the Schedule II substances are listed in 21 CFR 1308.12, not in 1308.11.
Is Schedule 1 or 5 the worst?
Schedule I is the most restrictive and Schedule V the least, in the sense of the statutory findings. Under 21 U.S.C. 812(b), Schedule I requires a high potential for abuse, no currently accepted medical use and a lack of accepted safety under medical supervision, while Schedule V requires a low potential for abuse relative to the drugs in Schedule IV, a currently accepted medical use, and limited physical or psychological dependence relative to Schedule IV. The statute’s wording for the schedules is comparative and runs I (highest abuse potential) to V (lowest). The data table below sets the five schedules side by side.
What is a class C controlled substance?
Under the federal Controlled Substances Act the categories are numbered schedules, I to V. The statute and regulation sections read for this page do not use letter classes such as “class C”. If a source sorts drugs into lettered classes, it is describing a different legal system or an informal grouping, so translate it to a schedule number and check the entry in sections 1308.11 to 1308.15 before relying on it.
Which drug is a Schedule 1 drug?
Any substance listed in 21 CFR 1308.11. Examples that appear in the section as checked 2026-11-19 include heroin (code 9200), lysergic acid diethylamide (7315), marihuana (7360), mescaline (7381), peyote (7415), psilocybin (7437), 3,4-methylenedioxymethamphetamine or MDMA (7405), methaqualone (2565) and cathinone (1235). Section 812(c) of the statute independently names heroin, mescaline and peyote among its initial Schedule I listings. The complete and current list is the section itself; use the paragraph map above to jump to the right type.
What Schedule I status requires of a research lab
Eligibility: who may hold Schedule I material for research
Section 1308.11 only lists substances; it does not authorize anyone to hold them. The research route is in 21 CFR 1301.18, which describes the research protocol for Schedule I substances. The protocol asks for the investigator’s name, address and DEA registration number if any, institutional affiliation, and qualifications including a curriculum vitae and bibliography. The registration side is covered in our guide to DEA researcher registration.
What the protocol must contain
Under 1301.18(a), the research-project part of the protocol includes: the title and a statement of purpose; the name of each controlled substance and the amount needed; a description of the research, including the number and species of research subjects, the dosage, the route and method of administration, and the duration; the location where research will be conducted; and a statement of the security provisions for storing and dispensing the substances in accordance with 21 CFR 1301.75 to prevent diversion. If the investigator wants to manufacture or import a listed substance, the protocol also states the quantity and the sources of chemicals or the substance to be imported. The authority part lists institutional approval, approval of a Human Research Committee for human studies, an approved active IND number where applicable, and an approved funded grant number, if any.
Application and compliance steps
- Identify the substance in 1308.11 by its chemical name and code number, and note the paragraph where it is listed.
- Assemble the protocol in the form 1301.18(a) sets out.
- For a clinical investigation, 1301.18(b) says the applicant submits three copies of a Notice of Claimed Investigational Exemption for a New Drug (IND) with a statement of security provisions to, and has them approved by, the Food and Drug Administration; that submission replaces the research protocol to DEA, and the applicant indicates it when applying for registration by submitting DEA Form 225 with three copies of the certificate set out in the section. See DEA Form 225.
- Store Schedule I material as 1301.75(a) requires: in a securely locked, substantially constructed cabinet. Section 1301.75(d) states the section also applies to nonpractitioners authorized to conduct research or chemical analysis under another registration. See DEA controlled substance storage requirements.
- Keep inventories as required; see controlled substance inventory and diversion prevention programs.
Typical phases, and when the protocol changes
The regulation describes a sequence rather than set durations. The phases are: identifying the listed substance; preparing the protocol and gathering institutional, Human Research Committee, IND and grant authorities; submission to DEA (or, for clinical investigations, the IND route to FDA with Form 225); registration; and conduct of the approved project. Two later events are written into the regulation. Under 1301.18(c), a registrant who wants to increase the quantity used for an approved research project submits a request to the Registration Unit, Drug Enforcement Administration, by registered mail, return receipt requested. Under 1301.18(d), research beyond the variations in the approved protocol (not counting a quantity increase) requires three copies of a supplemental protocol.
Common mistakes when using 1308.11
- Searching by common name only. Paragraph (a) lists names of several kinds and assigns a code number to each entry; use both a chemical name and the code.
- Skipping the paragraph lead-in. The “unless specifically excepted or unless listed in another schedule” wording and the isomer, ester, ether and salt coverage change what an entry includes, and the meaning of “isomer” differs in paragraph (d) and for 3-methylthiofentanyl in paragraph (b).
- Treating the list as static. Paragraph (h) entries are temporary listings with their own effective periods in the section’s notes.
- Treating a Schedule I listing as a registration. The listing defines the substance; the protocol and registration steps sit in part 1301.
- Ignoring exclusions inside an entry. The hemp carve-out in (d)(31)(ii) is an example.
Related schedules
The other four schedules follow the same pattern in neighbouring sections: 21 CFR 1308.12 (Schedule II), 1308.13 (Schedule III), 1308.14 (Schedule IV) and 1308.15 (Schedule V). Section 1308.12(a) opens with the same wording as 1308.11(a): the schedule consists of the substances “by whatever official name, common or usual name, chemical name, or brand name designated” listed in the section, each with a Controlled Substances Code Number. The data table below compares the statutory findings for all five schedules from 21 U.S.C. 812(b). For how substances move between schedules, see the Federal Register notices that amend part 1308; for the order form DEA uses for some scheduled substances, see our guide to DEA Form 222.
Frequently asked questions
What does it mean to be a Schedule II drug?
It means the substance is listed in 21 CFR 1308.12 and meets the 21 U.S.C. 812(b)(2) findings: high abuse potential, a currently accepted medical use (possibly with severe restrictions), and abuse that may lead to severe psychological or physical dependence.
Is schedule 1 or 5 the worst?
Schedule I is the most restrictive. Section 812(b) pairs Schedule I with a high potential for abuse and no currently accepted medical use, and Schedule V with a low potential for abuse relative to Schedule IV and a currently accepted medical use.
What is a class C controlled substance?
Federal law uses Schedules I to V, not lettered classes. Convert any “class” label to a schedule and check the substance’s entry in 21 CFR 1308.11 to 1308.15.
Which drug is a schedule 1 drug?
Any drug listed in 21 CFR 1308.11. Entries include heroin, LSD, marihuana, mescaline, peyote, psilocybin, MDMA, methaqualone and cathinone, among many others.
Does listing in 1308.11 mean a researcher cannot work with a substance?
No. Section 1301.18 sets out how research protocols for Schedule I substances are submitted, and part 1301 sets the security requirements, including locked, substantially constructed storage under 1301.75(a).
Sources
- Legal Information Institute, Cornell Law School: 21 CFR 1308.11, Schedule I, checked 2026-11-19
- Legal Information Institute, Cornell Law School: 21 CFR 1308.12, Schedule II, checked 2026-11-19
- Legal Information Institute, Cornell Law School: 21 CFR 1301.18, Research protocols, checked 2026-11-19
- Legal Information Institute, Cornell Law School: 21 CFR 1301.75, Physical security controls for practitioners, checked 2026-11-19
- U.S. Government Publishing Office: 21 U.S.C. 812, Schedules of controlled substances (2023 edition), checked 2026-11-19
Data: Statutory findings for each federal controlled substance schedule (21 U.S.C. 812(b))
Compares, schedule by schedule, the findings 21 U.S.C. 812(b) requires for placement in Schedules I to V and the CFR section that lists each schedule's substances. Compiled from the statute text on govinfo.gov and the Cornell Legal Information Institute copies of 21 CFR 1308.11 to 1308.15, read on 2026-11-19.
Period covered: Read 2026-11-19. Coverage: United States.
| Schedule | CFR section listing substances | Abuse potential finding | Accepted medical use finding | Dependence finding |
|---|---|---|---|---|
| Schedule I | 21 CFR 1308.11 | High potential for abuse | No currently accepted medical use in treatment in the United States; lack of accepted safety under medical supervision | Not stated in the Schedule I findings |
| Schedule II | 21 CFR 1308.12 | High potential for abuse | Currently accepted medical use in treatment in the United States, or accepted medical use with severe restrictions | Abuse may lead to severe psychological or physical dependence |
| Schedule III | 21 CFR 1308.13 | Potential for abuse less than the substances in Schedules I and II | Currently accepted medical use in treatment in the United States | Abuse may lead to moderate or low physical dependence or high psychological dependence |
| Schedule IV | 21 CFR 1308.14 | Low potential for abuse relative to Schedule III | Currently accepted medical use in treatment in the United States | Abuse may lead to limited physical or psychological dependence relative to Schedule III |
| Schedule V | 21 CFR 1308.15 | Low potential for abuse relative to Schedule IV | Currently accepted medical use in treatment in the United States | Abuse may lead to limited physical or psychological dependence relative to Schedule IV |
Sources
- 21 U.S.C. 812 (2023 edition), govinfo.gov (accessed 2026-11-19)
- 21 CFR 1308.11, Cornell LII (accessed 2026-11-19)
- 21 CFR 1308.12, Cornell LII (accessed 2026-11-19)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







